Mumbai-based API manufacturing company Supriya Lifescience announced on Monday that it has partnered with Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, to develop Quickblue, an oral cancer detection kit in India. With this, Supriya Lifescience aims to capture a one to two per cent market share of the global cancer market.
Quickblue is designed to detect oral cancer swiftly, eliminating the need for extensive preclinical and clinical trials. This development aligns with Supriya Lifescience’s vision of producing specialised products and becoming a global Contract Development and Manufacturing Organisation (CDMO) player.
This oral cancer detection kit offers a faster alternative to existing conventional methods, such as biopsies, and aims to be both more cost-effective and sensitive. With the global cancer market estimated at $21.5 billion, Supriya Lifescience aspires to capture a one to two per cent market share.
Saloni Wagh , Director, Supriya Lifescience stated “We expect the Quickblue oral cancer detection kit to be commercially available in the next 3 years. And after its launch we anticipate to capture the global cancer market share up to 1 or 2 percent in the next 1 year.”
Commenting on the development of Quickblue, Mrutyunjay Suar, director general of Research and Development and Innovation at Kalinga Institute of Industrial Technology University, stated, “We are extremely proud to be part of this collaboration with Supriya Lifescience for such a novel product. Our teams of scholars and faculty members worked diligently with the expert team at Supriya Lifescience to develop this product. We believe this product can be a lifesaver through early detection of oral cancer.”